The efficacy and safety of topical budezonide for pouchitis after restorative proctocolectomy in patients with ulcerative colitis.

The efficacy and safety of topical budezonide for pouchitis after restorative proctocolectomy in patients with ulcerative colitis. - The efficacy and safety of topical budezonide for pouchitis.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030000

Enrollment

Registered

2017-12-01

Start date

2018-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis pouchitis

Interventions

Topical budesonido 2weeks of 2mg daily Topical prednisolone 2weeks 20mg daily Topical aminosalicylate 2weeks 1g daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with agreement. Patients with pouchitis.

Exclusion criteria

Exclusion criteria: Patients without agreement. Patients with drug allergy.

Design outcomes

Primary

Measure	Time frame
The remission rate after 2weeks of treatment.	—

Secondary

Measure	Time frame
The change of pouchitis disease activity index score during 2weeks of treatment. The rate of adverse events.	—

Countries

Japan

Contacts

Public ContactMotoi Uchino

Hyogo College of Medicine Department of Inflammatory Bowel Disease

uchino2s@hyo-med.ac.jp0798-45-6371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026